Haemonetics Corp. (HAE) Misses Q4 EPS by 3c; Guides FY13 EPS Below Views

Haemonetics Corp. (NYSE: HAE) reported Q4 EPS of $0.80, $0.03 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $186.7 million versus the consensus estimate of $183.09 million.

Haemonetics Corp. sees FY2013 EPS of $3.30-$3.40, versus the consensus of $3.50.

For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• S&P 500 eyes record as retail slump, Iran risk set up pivotal week
• Rothschild Redburn Upgrades Apple (AAPL) to Buy